Cancer Drug Labels Often Do Not List Data On Survival After Treatment, Study Finds
Dec 19, 2023
Many newly approved cancer drugs fail to clearly communicate survival benefits associated with their use on the label, according to an analysis published Monday by JAMA Internal Medicine. Of the 125 drugs designed to treat cancer approved by the U.S. Food and Drug Administration between 2014 and 2018, 22 included evidence on their effects on overall survival on their package insert — the detailed information on effectiveness, safety and side effects provided — the data showed.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…